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Acute respiratory distress syndrome
Acute lung injuryObjective: Animal studies suggested that angiotensin-converting enzyme inhibitors (ACEi) and
angiotensin-receptor blockers (ARB) facilitate the inoculation of potentially leading to a higher risk of
infection and/or disease severity. We aimed to systematically evaluate the risk of COVID-19 infection
and the risk of severe COVID-19 disease associated with previous exposure to (ACEi) and/or ARB).
Methods: MEDLINE, CENTRAL, PsycINFO, Web of Science Core Collection were searched in June 2020 for
controlled studies. Eligible studies were included and random-effects meta-analyses were performed.
The estimates were expressed as odds ratios (OR) and 95% confidence intervals (95%CI). Heterogeneity
was assessed with I2 test. The confidence in the pooled evidence was appraised using the GRADE frame-
work.
Results: Twenty-seven studies were included in the review. ACEi/ARB exposure did not increase the risk
of having a positive test for COVID-19 infection (OR 0.99, 95%CI 0.89–1.11; I2 = 36%; 5 studies, GRADE
confidence moderate). The exposure to ACEi/ARB did not increase the risk of all-cause mortality among
patients with COVID-19 (OR 0.91, 95%CI 0.74–1.11; I2 = 20%; 17 studies; GRADE confidence low) nor sev-
ere/critical COVID-19 disease (OR 0.90, 95%CI 0.74–1.11; I2 = 55%; 17 studies; GRADE confidence very
low). Exploratory analyses in studies enrolling hypertensive patients showed a association of ACEi/ARB
with a significant decrease of mortality risk.
Conclusions: ACEi/ARB exposure does not seem to increase the risk of having the SARS-CoV-2 infection or
developing severe stages of the disease including mortality. The potential benefits observed in mortality
of hypertensive patients reassure safety, but robust studies are required to increase the confidence in the
results.
 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The novel acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) firstly identified in Wuhan China lead to a world-wide out-
break pandemic situation with more than 350,000 related deaths
[1]. The SARS-CoV-2 goes into the host cells through theangiotensin-converting enzyme (ACE) 2 (ACE2) receptor [2]. Some
animal studies showed that angiotensin-converting enzyme inhi-
bitors (ACEi) and angiotensin-receptor blockers (ARB) increase
the ACE2, creating the hypothesis that these drugs could facilitate
the inoculation of SARS-CoV-2 potentially leading to a higher risk
of infection and/or disease severity [3]. The fragility of these
assumptions led several medical societies to issue a recommenda-
tion for not withdrawing these drugs because the evidence was not
compelling and due to the potential harms, as these drugs are
effective treatments in the management of hypertension, diabetes
mellitus, coronary heart disease, cerebrovascular disease and/or
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we aimed to assess the risk of infection by SARS-CoV-2 and the risk
of mortality or respiratory complications in patients with symp-
tomatic disease of SARS-CoV-2 (COVID-19) related to previous
use of ACEi or ARBs.2. Methods
This systematic review followed the reporting principles of
MOOSE and PRISMA [4,5]. The protocol is available at https://osf.
io/6vf2w. Patients and public were not involved in this review.2.1. Eligibility criteria
We included all controlled studies with information about risk
of infection or the risk of disease complications associated with
ACEi and/or ARBs.
For randomized controlled trials or cohort/nested case-control
studies that evaluated the risk of infection (positive test), studies
had to enrol a population submitted to tests and to report the risk
of having a positive test associated with ACEi and/or ARB, or having
raw data that enables these calculations.
Regarding the risk of disease complications, studies had to eval-
uate the risk of mortality/severe disease associated with ACEi and/
or ARB use compared with patients not treated with these drugs,
both from a population perspective or among population infected
with SARS-CoV-2. ACEi or ARBs had to be reported by the investi-
gators as a group (ACEi/ARB) or individually. We accepted controls
treated with other antihypertensive drugs or without any antihy-
pertensive drug.
In case-control studies, cases were patients with COVID-19
infection (positive test) irrespective of disease severity, and con-
trols were matched individuals without the referred outcomes.
Data about ACEi and/or ARB risks should be available.
The outcomes of interest were:
1) COVID-19 infection documented by nasophaygeal or
oropharyngeal swab tests or reported by authors as having
COVID-19;
2) All-cause Mortality;
3) Severe/Critical Disease according with the World Health
Organization and Chinese Centre of Disease Control [6,7].
Whenever possible, if adequate, adjusted measures were
retrieved particularly for observational studies, giving preference
to propensity score matching or weighting.2.2. Search methods for study identification
The reviewers performed an electronic database search through
MEDLINE, CENTRAL, PsycINFO and Web of Science Core Collection
databases for relevant studies (Search strategy at Supplementary
Table 1). The database medRxiv was also searched for unpublished
pre-print manuscripts for an exploratory analysis. Relevant
reviews obtained in the searching process as well as the references
of potentially included studies were analysed in order to search for
potential eligible studies. There were no restrictions on language or
publication date. The search lastly performed at 8th June 2020.2.3. Study selection and data collection process
The title and abstract screening phase of records yielded by the
search was performed independently by clusters of 2 reviewers.
Disagreements were resolved through consensus or by a thirdreviewer (DC). The studies that were not excluded went to the
full-text assessment phase.
The reasons for exclusion were recorded at this stage.
The reviewers extracted study data following a pre-established
data collection form. When studies presented different estimates
of the outcome of interest, we extracted the most precise or
adjusted measures.
Risk of bias was independently evaluated by three authors (DC,
MA, ANF) using the Cochrane Risk of Bias Tool for randomized con-
trolled trials and ROBINS-I tool for observational studies [8,9]. The
studies were qualitatively classified as at critical, serious, moder-
ate, or low risk of bias. Risk of bias graphs were derived from these
tools.
2.4. Statistical analysis and pooled data evaluation
We used Review Manager for statistical analysis and to derive
forest plots. We used the inverse variance method and random-
effects model to pool data. We reported pooled dichotomous data
using odds ratios (OR) with their 95% confidence intervals (95%
CIs). Heterogeneity was assessed using I2 [10]. We present effect
estimates as OR because relative estimates are more similar across
studies with different designs, populations and lengths of follow-
up than absolute effects [11]. We used the hazard ratio (HR) when
OR was not available nor possible to calculate. Publication bias
assessment was performed through funnel plot examination and
Egger test providing that a sufficient number of studies were
included [12].
Exploratory analyses were performed with adjusted estimates,
and only those with data of hypertensive patients. We further per-
formed an additional exploratory analysis including unpublished
(Preprint) studies found in medRxiv.
We used the Grading of Recommendations, Assessment, and
Evaluation (GRADE) framework to report the overall quality of evi-
dence. The certainty in the evidence for each outcome was graded
as high, moderate, low, or very low [13].3. Results
3.1. Included studies
The search returned 528 records, resulting in 27 study records
after the deduplication, title and abstract screening and full-text
screening (Fig. 1; details of excluded studies at Supplementary
Table 2) [14–40]. There was one randomized controlled trial (a
non-prespecified interim analysis of an open-label trial), 4 case-
control studies (two of them – Gnavi et al – were reported in the
same article) and the remaining were cohort/nested case-control
studies.
The main characteristics of the included studies are depicted in
Table 1. The median sample size was 522 [interquartile range 113–
4051] and overall, there were 119,656 participants evaluated.
3.2. Risk of bias
The risk of bias in the included studies was moderate for studies
evaluating the risk of infection, while those assessing the infection
severity/mortality were classified as serious. The only randomized
controlled trial had an open-label design, a small sample size
(n = 102) and was not designed to assess COVID-19 outcomes as
the reported results were from a non-prespecified interim analysis.
The lack of outcome adjustments for important clinical factors was
the main source of risk of bias. Supplementary Table 3 details the
risk of bias for each study according with the outcome. Supplemen-
tary Fig. 1 overviews the proportions of risk of bias categories.
Fig. 1. Flowchart of studies selection process.
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ARB
Six cohorts had information about COVID-19 infection (positive
test) and ACEi and/or ARB. In the meta-analysis the ACEi/ARB
group was not associated with increased risk of having a positive
test for COVID-19 infection (OR 0.99, 95%CI 0.91–1.11; I2 = 36%;
6 studies; Fig. 2), nor ACEi (OR 0.94, 95%CI 0.87–1.02; I2 = 0%; 7
studies) or ARB (OR 1.01, 95%CI 0.93–1.10; I2 = 11%; 6 studies)
(Supplementary Figs. 2 and 3), individually.
3.4. Mortality risk associated with ACEi/ARB among patients with
COVID-19 infection
Regarding all-cause mortality, ACEi or ARB were associated with
neither an increased nor reduction in the risk this outcome: ACEi/
ARB, OR 0.91, 95%CI 0.74–1.11, I2 = 20%, 17 studies, Fig. 2); ACEi, OR
0.85, 95%CI 0.40–1.78, I2 = 0%, 4 studies; and ARB OR 0.80, 95%CI
0.47–1.35, I2 = 0%, 3 studies (Fig. 3; Supplementary Figs. 2 and 3).
3.5. Risk of severe disease associated with ACEi/ARB among patients
with COVID-19 infection
The risk of severe COVID-19 disease associated with ACEi/ARB
(OR 0.90, 95%CI 0.74–1.11; I2 = 55%; 17 studies; Fig. 2), ACEi (OR
1.05, 95%CI 0.64–1.70; I2 = 63%; 4 studies) or ARB (OR 1.32, 95%
CI 0.75–2.30; I2 = 86%; 6 studies) individually was not significantly
increased nor decreased (Fig. 3; Supplementary Figs. 2 and 3).
3.6. Risk of severe disease associated with ACEi/ARB compared with
populational controls
Two case-control studies evaluated the risk of severe COVID-19
associated with ACEi/ARB using populational controls as reference[17,27]. One only study had data about a grouped estimate of ACEi/
ARB and the results did not support the hypothesis that ACEi/ARB
was associated with severe COVID-19 (OR 1.08, 95%CI 0.79–1.47; 1
study) [27]. Two studies supplied data for ACEi and ARB individu-
ally [17,27], and the pooled estimates for both evaluations showed
no significant effects (ACEi: OR 0.91, 95% 0.72–1-14; I2 = 0%, 2 stud-
ies; ARB: 1.01, 95%CI 0.67–1.50; I2 = 69%; 2 studies; Fig. 3; Supple-
mentary Figs. 2 and 3).
3.7. Publication bias risk assessment
We performed the Egger test in the evaluations of ACEi/ARB
with more than 10 studies to determine whether publication bias
exists. The Egger test was not statistically significant in the risk
of having COVID-19 infection (p-value 0.64), risk of mortality
among those symptomatic COVID-19 (p-value 0.09), and risk of
severe disease among those with COVID (p-value 0.42). The funnel
plots are depicted in Supplementary Figure 4.
3.8. Sub-analyses
We performed sub-analyses of ACEi/ARB association including
only studies with adjusted estimates, hypertensive patients, and
including unpublished data (Fig. 3).
The analysis of studies with adjusted estimates did not find any
significant association between ACEi/ARB and risk of infection (OR
0.99, 95%CI 0.89–1.11, I2 = 35%, 5 studies), mortality (OR 0.90, 95%
CI 0.68–1.18, I2 = 27%) and severe/critical disease (OR 0.88, 95%CI
0.63–1.22, I2 = 68%) among patients with COVID-19 (Fig. 3, Supple-
mentary Figure 5).
Analysing only the data from hypertensive patients, the risk of
developing the infection in patients treated with ACEi/ARB was
not significantly increased (OR 0.97, 95%CI 0.85–1.11; I2 = 38%)
(Fig. 3, Supplementary Figure 6). The mortality risk (OR 0.76, 95%
Table 1
Main characteristics of included studies.
Study Year Design Region Population Total/ ACEi/
ARB
Control Mean-median
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Table 1 (continued)
Study Year Design Region Population Total/ ACEi/
ARB
Control Mean-median
































N = 1317 positive
















































































































































































































(continued on next page)
D. Caldeira et al. / IJC Heart & Vasculature 31 (2020) 100627 5
Table 1 (continued)
Study Year Design Region Population Total/ ACEi/
ARB
Control Mean-median
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Table 1 (continued)
Study Year Design Region Population Total/ ACEi/
ARB
Control Mean-median
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Table 1 (continued)
Study Year Design Region Population Total/ ACEi/
ARB
Control Mean-median
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and the number of
anti-hypertensive
agents used for the
patient
*with a diagnosis of ischaemic heart disease (ICD9CM at discharge 410–414), cerebrovascular disease (430–438), or heart failure (428), and persons registered in the regional
register of persons with diabetes.
Legend: RT-CPR reverse transcriptase-polymerase chain reaction; ACEi Angiotensin-converting-enzyme inhibitors; ARB angiotensin receptor blocker; RAAS renin-angio-
tensin-aldosterone system; SES socioeconomic status; BMI body mass index; HTN hypertension; CAD coronary artery disease; HF heart failure; DM diabetes mellitus; CKD
chronic kidney disease; MI myocardial infarction; COPD Chronic obstructive pulmonary disease; CHD chronic heart disease; PCI percutaneous coronary intervention; PSM:
Propensity-score matching CABG coronary artery bypass graft; NSAID Nonsteroidal anti-inflammatory drugs; GI gastrointestinal; CT computed tomography; CRP c-reactive
protein; pts patients.
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while the risk of developing severe disease (OR 0.91, 95%CI 0.69–
1.21; I2 = 64%) was not statistically significant (Fig. 3, Supplemen-
tary Figure 6).
Considering both published and unpublished data retrieved
from 7 additional studies (supplementary Table 4), there was a
non-statistically significant association between ACEi/ARB and
decreased mortality risk among COVID-19 patients (OR 0.79, 95%
CI 0.62–1.00, I2 = 0%) (Fig. 3, Supplementary Figure 5). The risk of
infection (OR 0.99, 95%CI 0.91–1.09, I2 = 20%) and the risk of sev-
ere/critical disease (OR 0.89, 95%CI 0.70–1.14, I2 = 59%) were nei-
ther significantly increased nor decreased (Fig. 3, Supplementary
Figure 7).3.8.1. Assessment of confidence in cumulative evidence
Table 2 presents a summary of findings table which summa-
rizes the results obtained only for the associations found for
grouped ACEi/ARB exposure, according to certainty of the evidence
(GRADE). The current evidence is that ACEi/ARB use is not associ-
ated with increased clinically significant risk of having a positive
test with moderate confidence. Mortality risk among COVID-19
patients was significantly decreased, but the confidence of these
data was graded as low (Table 2). The confidence concerning the
association of ACEi/ARB and risk severe/critical disease among
COVID-19 patients was very low (Table 2).4. Discussion
The main finding of this systematic review was that ACEi/ARB
were not associated with increased risk of being infected (moder-
ate confidence), and among patients with COVID-19 the exposure
to ACEi/ARB did not increase the risk of severe disease (very low
confidence) or mortality (low confidence). In our exploratory anal-
ysis that only included hypertensive patients, ACEi/ARB were asso-
ciated with a decreased mortality risk among COVID-19 patients
however the data quality/risk of bias and the fragility of thisexploratory analysis precludes definite and robust conclusions
about the potential benefit. The other exploratory analyses also
did not suggest harm, assuring the safety for the use of these drugs.
The rationale for this research was mainly based on the corre-
spondence publication of Lancet Respiratory Medicine where Lei
Fang and colleagues found that a significant number of patients
with severe infection or death from SARS-CoV-2 were hyperten-
sive, diabetic or had cardio-cerebrovascular disease and that these
conditions are often treated with ACEi or ARB [3]. They hypothe-
sized that the risk of infection or death might be increased in this
group of patients due to an increase in the expression of ACE2
which can facilitate the entrance of SARS-CoV-2 into the cells [3].
The publication gained prominence in the scientific community
and led to alarmism in the non-scientific community, given the
high number of patients taking these drugs.
Given that the suspension of ACEI or ARBs can lead to decom-
pensation of the underlying pathologies and there were no robust
studies to corroborate the aforementioned hypothesis (data from
only small preclinical studies), this led to some of the main scien-
tific societies such as the American Heart Association, the Ameri-
can College of Cardiology, the Council on Hypertension of the
European Society of Cardiology, and European Society of Hyperten-
sion, to publish recommendations to warn against discontinuing
these drugs in the absence of clear clinical evidence of harm [41].
Our data are important because they validate these
recommendations.
Despite ACEi and ARB having pharmacodynamic effects in the
same pathway, the specific site of drug action may hypothetically
lead to different effects, particularly in the risk of infectious dis-
eases. Previous systematic review evaluating the potential role of
ACEi in the prevention of pneumonia [42]. At that time the putative
protective mechanism was thought to be related with enhanced
cough reflex related to bradykinin and substance P, both derived
from the inhibition of ACE [42]. Nowadays, the mechanisms are
still speculative but hypothetically both ACEi and ARB may provide
lung protection through the activation of angiotensin II-receptors
type 2 (AT2R) and Mas receptors. The potential role of ACE2 in
Fig. 2. Forest plots of ACEi/ARB association with the risk of COVID-19 infection and disease severity.
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increase may supply pathways for SARS-CoV-2 entrance into the
cells [2], it is known that cleaved and shedded ACE2 leads to the
breakdown of Angiotensin II to Angiotensin 1-7 (directly or indi-
rectly increased with ARB or ACEi, respectively) have anti-
inflammatory and anti-fibrotic effect through Mas receptors
[41,43]. The SARS-CoV-2 infection also leads to a downregulation
of ACE2, that was associated with increased lung injury in animal
models [44,45]. Despite these ambiguous roles of ACE2, it is impor-
tant to mention that relationship of serum/urinary ACE2 and tissue
concentrations and use of ACEi/ARB is not well established, partic-
ularly in humans [46–48], and the clinical relevance of such rela-
tionships point towards a neutral effect according to our data. In
order to further explore the potential role ACE2 and ACEi/ARB in
the Influenza A infection, which share the same lung injury path-
way as SARS-CoV-2, Chung et al analyzed the data of more than
5 million people in the UK followed for a median of 8.7 yearsand they found that ACEi and ARB exposure were associated with
a decreased risk of Influenza A infection [49].
The data of this review are also important to reassure the safety
of ACEi/ARB after the retraction of a large observational study that
supported the safety of ACEi/ARB and showed a potential associa-
tion of ACEi with lower COVID-19 mortality (Mehra MR et al N Eng
J Med 2020). The authors asked for paper retraction after some
concerns about the study and the impossibility of having a third
party review on their data and analyses. Therefore, and despite
the retraction, considering our data (without the retracted study),
it seems reasonable to claim that ACEi/ARB are not harmful,
despite the limitations reflected in the GRADE confidence. This
supports the recommendations for not stopping the therapeutic
use of ACEi/ARB. For potential benefit assessment, as seen in the
hypertensive subgroup, further studies, such as the Elimination
or prolongation of ACE inhibitors and ARB in Coronavirus Disease
2019 (REPLACECOVID) or Stopping ACE-inhibitors in COVID-19
Fig. 3. Forest plots of ACEi or ARB association with the risk of COVID-19 infection and disease severity, and the results of subanalyses of ACEi/ARB.
Table 2
Summary of finding table with the GRADE approach.
Outcomes № of studies Certainty of the evidence





























*The threshold for clinically significant effect (harm) was arbitrarily established as
an increase of 25% in the odds of the outcome (a measure suggested by GRADE
[43]).
CI: Confidence interval; OR: Odds ratio.
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will provide more insights.
Our data are limited by the studies risk of bias which includes
their observational nature for most of them. Pooling data of studies
with different designs that evaluated different populations should
also be considered as a potential limitation. Nevertheless, it
increases the power and external validity of obtained data. In some
studies, the risk of severe/critical disease was retrieved from speci-
fic outcomes such as the need of mechanical invasive ventilation or
acute respiratory distress syndrome. This could explain the hetero-
geneity found in this outcome, but exclusion of these studies did
not decrease the statistical heterogeneity and it remained substan-
tial in the sub-analyses (data not shown). Lastly in these results
only reflect the impact of ACEi and/or ARB. Other modulators of
the renin-angiotensin-aldosterone system such renin inhibitors
(aliskiren), mineralocorticoid receptor antagonists (spironolactone
or epleronone), or even sacubitril were not evaluated in this
review. In fact these drugs are residual considering the prescription
of ACEi or ARB that in the de Abajo study we used the odds ratio of
renin-angiotensin-aldosterone inhibitors as ACEi and ARB repre-sented more than 90% of patients treated with the drugs of this
group [27].
5. Conclusions
Our systematic review with meta-analysis did not suggest that
the exposure to ACEi/ARB increases the risk of having the SARS-
CoV-2 infection or developing severe stages of the disease, which
supports the position papers of several medical associations rec-
ommending for not withholding these drugs in people already
treated with them. Our data also showed a statistically significant
association between ACEi/ARB exposure and reduction in COVID-
19 mortality in hypertensive patients, but the frailty of the data
and analysis precludes definite conclusions and emphasizes the
need of further robust data.
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